News

Albemarle High School Teen Competes for Virginia

Virginia Bio and the Virginia Bioscience Foundation have named Albemarle High School’s, Meenakshi “Meena” Ambati, as the winner of the 2021 Virginia BioGENEius Challenge, the premier competition for high school students that recognizes outstanding research and innovation in the biotechnology field. As the Virginia BioGENEius finalist, Meena will attend the 2021 BIO Digital Conference, where she will engage with leading companies, scientists and innovators currently transforming the scientific landscape in order to gain invaluable insights into an industry making significant contributions to the world.

Meena’s project was titled “Identification of Fluoxetine as a direct NLRP3 inhibitor to treat atrophic macular degeneration: Molecular modeling, Mechanism, Morphometry, and Meta-analysis (Year 2)”. The project was selected by an independent panel of volunteer judges representing the Virginia Bio membership.

Recent News

01/18/2026

Gerry Brunk Joins Focused Ultrasound Foundation’s Council

The Foundation is pleased to welcome Gerry Brunk to its Council, a committed group of goodwill ambassadors who partner with the Board of Directors and staff to offer guidance, raise funds, and generate awareness for focused ultrasound technology. Mr. Brunk co-founded Lumira Ventures, a North American healthcare venture capital firm, and serves as managing director in the firm’s Boston office. He has led investments in

01/12/2026

Nanochon closes $4.1M Seed Prime II Funding Round

Nanochon, a Washington, DC-based orthopedic device company developing an implant for treating articular cartilage defects in the knee, has secured commitments to close an oversubscribed funding round, bringing its total capital raised to date to $11.3 million. The round was led by cultivate(MD), with significant contributions from The University of Virginia UVA Seed Fund, WSGR,

01/07/2026

ReAlta Life Sciences Announces Appointment of Jonathan Rigby to Board of Directors

ReAlta Life Sciences Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company focused on safely targeting neutrophils and central components of the complement system to revolutionize the treatment of inflammatory disorders, today announced the appointment of Jonathan Rigby as a member of the ReAlta Life Sciences Board of Directors. Howard Berman, Ph.D., executive chairman, stated: